These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 759278)

  • 1. [Biological availability of Ossin, a sodium-fluoride dragee for osteoporosis therapy].
    Becker R
    Fortschr Med; 1979 Jan; 97(1):39-42. PubMed ID: 759278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoride pharmacokinetics: its implications in the fluoride treatment of osteoporosis.
    Ekstrand J; Spak CJ
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S53-61. PubMed ID: 2339637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bioavailability of monofluoride preparations for dental caries prophylaxis (author's transl)].
    Fuchs C; Férault-Larue DH; Heimann G
    Arzneimittelforschung; 1980; 30(2):333-5. PubMed ID: 7378115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of food on relative bioavailability of fluoride in man from Na2FPO3-containing tablets for the treatment of osteoporosis.
    Trautner K
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):242-9. PubMed ID: 2737790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoride therapy in metabolic bone disease.
    Spencer H; Kramer L; Wiatrowski E; Lender M
    Isr J Med Sci; 1984 May; 20(5):373-80. PubMed ID: 6469556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attainment of therapeutic fluoride levels in serum without major side effects using a slow-release preparation of sodium fluoride in postmenopausal osteoporosis.
    Pak CY; Sakhaee K; Gallagher C; Parcel C; Peterson R; Zerwekh JE; Lemke M; Britton F; Hsu MC; Adams B
    J Bone Miner Res; 1986 Dec; 1(6):563-71. PubMed ID: 3503562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro release and in vivo serum fluoride levels and urinary excretion after different sodium fluoride tablets.
    Hasvold O; Ekren T
    Eur J Clin Pharmacol; 1981 Feb; 19(3):225-30. PubMed ID: 7215422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestinal absorption of fluoride preparations.
    Deka RC; Kacker SK; Shambaugh GE
    Laryngoscope; 1978 Dec; 88(12):1918-21. PubMed ID: 732493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between fluoride effects on bone histology and on bone mass in patients with postmenopausal osteoporosis.
    Harrison JE; Bayley TA; Josse RG; Murray TM; Sturtridge W; Williams C; Goodwin S; Tam C; Fornasier V
    Bone Miner; 1986 Sep; 1(4):321-33. PubMed ID: 3504712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability and pharmacokinetic characteristics of two monofluorophosphate preparations with calcium supplement.
    Setnikar I; Rovati LC; Schmid K; Vens-Cappell B; Barkworth MF
    Arzneimittelforschung; 1998 Dec; 48(12):1172-8. PubMed ID: 9893933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of enteric-coated sodium fluoride tablets as affected by the administration of calcium supplements at different time intervals.
    Devogelaer JP; Nagant de Deuxchaisnes C; Stein F
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S75-9. PubMed ID: 2339640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 7. Fluoride therapy for osteoporosis.
    Murray TM; Ste-Marie LG
    CMAJ; 1996 Oct; 155(7):949-54. PubMed ID: 8837545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Problems of large dose therapy with sodium fluoride in osteoporosis].
    Heidelmann G
    Z Arztl Fortbild (Jena); 1979 May; 73(9):431-5. PubMed ID: 483886
    [No Abstract]   [Full Text] [Related]  

  • 14. Relative bioavailability of fluoride from monofluorophosphate tablets after single oral administration.
    Setnikar I; Maurer H
    Arzneimittelforschung; 1990 Mar; 40(3):323-8. PubMed ID: 2346544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experience with treatment of osteoporosis with Ossin (author's transl)].
    Nemec M; Kovác M; Varga G; Nemec P
    Acta Chir Orthop Traumatol Cech; 1981; 48(6):557-61. PubMed ID: 7324737
    [No Abstract]   [Full Text] [Related]  

  • 16. Fluoride and osteoporosis.
    Franke J
    Ann Chir Gynaecol; 1988; 77(5-6):235-45. PubMed ID: 3076051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bioavailability of fluorides from various salts and from various dietary components].
    Patz J; Henschler D; Fickenscher H
    Dtsch Zahnarztl Z; 1977 Jun; 32(6):482-6. PubMed ID: 267572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of the bioavailability of fluoride after the administration of sodium fluoride alone or combined with calcium].
    Briancon D; Quillet P; Duplan B; Chapuy MC; Arlot M; Meunier PJ
    Therapie; 1988; 43(2):107-10. PubMed ID: 3406928
    [No Abstract]   [Full Text] [Related]  

  • 19. In postmenopausal osteoporosis the bone increasing effect of monofluorophosphate is not dependent on serum fluoride.
    Rigalli A; Pera L; Morosano M; Masoni A; Bocanera R; Tozzini R; Puche RC
    Medicina (B Aires); 1999; 59(2):157-61. PubMed ID: 10413893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal absorption of fluoride at high luminal concentration of fluoride.
    Rigalli A; Beinlich A; Puche RC
    Arzneimittelforschung; 2001 Feb; 51(2):151-5. PubMed ID: 11258045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.